SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2i) SHORT-TERM OUTCOME IN DIABETIC KIDNEY TRANSPLANT RECIPIENTS

摘要

Introduction: The emergence of positive data on the use of sodiumglucose co-transporter inhibitors (SGLT2i) in the last several years, begged the question of whether their positive outcomes can be seen in kidney transplant recipients, as they have the same and even more pronounced cardiovascular risk factors than the general population and in addition, we got better in improving graft and patients survival in the short term, but we lack the tools to improve long term patients and graft survival where so many patients die from cardiovascular disease with a functioning graft or lose their graft from chronic changes and chronic antibody-mediated rejection with difficult to control blood pressure and proteinuria.